Skip to content

Study · Case report or series · n = 1 · 2024

2 results

Acute Pancreatitis Likely Due to Semaglutide.

Hughes K, Sumaruth YRK, Mohammed E, Sant Bakshsingh V

Cureus21 Sept 2024Cited by 5 (Europe PMC)

PMID39308839 (opens in a new tab)PMCIDPMC11416045 (opens in a new tab)DOI10.7759/cureus.69844 (opens in a new tab)PepBankPUB-39308839
Download PDFPubMedAsk about this study
Jump to 2 results

Summary

Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1RA) that has gained recent popularity in its effective management of type 2 diabetes mellitus (T2DM) and obesity. Minimal evidence has reported the link between Semaglutide use and acute pancreatitis. In this case report, we discuss the case of a 36-year-old female presenting to the Emergency Department with sudden-onset epigastric pain, subsequently diagnosed with acute pancreatitis. Moreover, she had recently started subcutaneous semaglutide injections for weight loss, which she had procured from one of her acquaintances without seeking medical advice. Semaglutide was thus stopped and her lipase levels normalized with significant improvement of her symptoms, making semaglutide the likely causative factor for her acute pancreatitis. Given the increased use of GLP-1RA, we aim to increase awareness among patients taking this medication whether prescribed or not and increase clinician awareness when prescribing this medication.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanCase report or seriesSafety outcome

    In a 36-year-old woman who recently started subcutaneous semaglutide for weight loss, acute pancreatitis was likely caused by semaglutide.

    In plain wordsIn one woman who recently started semaglutide injections, doctors judged semaglutide the likely cause of her acute pancreatitis.

    Peptide
    Semaglutide
    Outcome
    Not applicableAcute pancreatitis
    Study

    n = 1

    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Semaglutide was thus stopped and her lipase levels normalized with significant improvement of her symptoms, making semaglutide the likely causative factor for her acute pancreatitis.
    2 context sentences
    Summary · context
    In this case report, we discuss the case of a 36-year-old female presenting to the Emergency Department with sudden-onset epigastric pain, subsequently diagnosed with acute pancreatitis.
    Summary · context
    Moreover, she had recently started subcutaneous semaglutide injections for weight loss, which she had procured from one of her acquaintances without seeking medical advice.
  2. 02HumanCase report or seriesSafety outcome

    In a 36-year-old woman with acute pancreatitis, lipase levels normalized and symptoms improved significantly after semaglutide was stopped.

    In plain wordsIn one woman with pancreatitis, lipase levels returned to normal and symptoms improved after semaglutide was stopped.

    Peptide
    Semaglutide
    Outcome
    Not applicableLipase and symptoms after stopping semaglutide
    Study

    n = 1

    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Semaglutide was thus stopped and her lipase levels normalized with significant improvement of her symptoms
    2 context sentences
    Summary · context
    In this case report, we discuss the case of a 36-year-old female presenting to the Emergency Department with sudden-onset epigastric pain, subsequently diagnosed with acute pancreatitis.
    Summary · context
    Moreover, she had recently started subcutaneous semaglutide injections for weight loss, which she had procured from one of her acquaintances without seeking medical advice.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.